“We admit it,” the estrogen receptor-positive cancer cells said, probably while wearing tiny villain capes, “we were hoping everyone would keep attacking us with chemo forever and forget about our hormone habit.”
That, in miniature, is the story behind the FAMILY trial: a phase 3 study asking a very practical question in metastatic breast cancer. After first-line chemotherapy gets hormone receptor-positive, HER2-negative metastatic breast cancer under control, what should come next? Keep using a chemo pill like capecitabine? Or switch to fulvestrant, a hormone-blocking drug that goes after the estrogen receptor like someone confiscating the tumor’s favorite snack machine?
The answer, at least in this trial, leaned toward fulvestrant.
The Cancer Subtype With a Subscription to Estrogen
Hormone receptor-positive breast cancers carry estrogen and/or progesterone receptors. That means many of these tumors use hormone signals to grow. Not politely, obviously. Cancer biology never sends a calendar invite.
HER2-negative means the tumor is not mainly driven by extra HER2 signaling. Put those together and you get HR-positive, HER2-negative breast cancer, the most common metastatic breast cancer subtype. Modern treatment often starts with endocrine therapy plus a CDK4/6 inhibitor, which is basically putting the cancer cell cycle in time-out. Reviews in JAMA Oncology and Cancer Treatment Reviews describe how much that strategy has reshaped care, while also making one thing painfully clear: sequencing treatments is still a giant, expensive game of clinical Tetris O’Sullivan et al., 2023; Gennari et al., 2024.
But some patients still need chemotherapy early, especially when disease is moving fast or affecting vital organs. Once chemo has calmed things down, doctors face the maintenance question: what keeps the peace without making everyday life feel like a side quest in a very unpleasant video game?
Fulvestrant Versus Capecitabine: The Matchup
Capecitabine is an oral chemotherapy drug that turns into 5-FU in the body. It can be useful, but chemo is chemo. It can bring diarrhea, hand-foot syndrome, fatigue, low blood counts, and the general vibe of “my cells and I are having a workplace dispute.”
Fulvestrant is different. It is a selective estrogen receptor degrader, or SERD. Translation: it binds the estrogen receptor and helps mark it for disposal. Not just “please stop listening to estrogen,” but “please remove the antenna from the roof.”
In the FAMILY trial, researchers enrolled 210 women across 22 hospitals in mainland China. All had HR-positive, HER2-negative metastatic breast cancer that had responded to or at least stabilized after first-line chemotherapy. Half received fulvestrant maintenance, and half received capecitabine maintenance Wu et al., 2026.
The main result: median progression-free survival was 17.3 months with fulvestrant versus 9.0 months with capecitabine. That is not a tiny shrug of a difference. That is the difference between the disease staying controlled for about a year and a half versus about nine months, on average. The hazard ratio was 0.63, meaning the fulvestrant group had a lower risk of progression or death during the study period.
Overall survival data were not mature yet, which is scientist-speak for “don’t make the victory banner too large until the next scan of the evidence.”
The Side Effect Department Was Also Paying Attention
The safety results mattered because maintenance therapy is supposed to maintain. Not flatten people. Not turn Tuesday into a pharmaceutical obstacle course.
Grade 3 or worse adverse events happened in 2.9% of patients on fulvestrant and 10.5% on capecitabine. Nobody in the fulvestrant group stopped treatment because of side effects, compared with 7.6% in the capecitabine group. That matters in real life, where “tolerable” is not a decorative word in a trial table. It is whether someone can eat dinner, walk outside, sleep, work, travel, parent, or simply have a day that is not entirely sponsored by nausea.
Why This Is More Than a Drug Duel
This study fits into a bigger shift in HR-positive metastatic breast cancer: use targeted endocrine approaches when the biology still offers that opening, and save harsher tools for when they are truly needed. Newer reviews point toward increasingly personalized treatment, with molecular testing, SERDs, PI3K/AKT/mTOR pathway drugs, antibody-drug conjugates, and other strategies changing the treatment map Ferro et al., 2024; Bidard et al., 2024.
Does FAMILY settle every question? Nope. It was open-label, conducted in China, and it studied a specific post-chemotherapy situation. It also does not erase the role of CDK4/6 inhibitors or newer targeted therapies. Cancer treatment is not a single escalator. It is more like airport security during a thunderstorm: many lines, lots of rules, and somehow everyone is still holding paperwork.
But the trial gives doctors and patients useful evidence for a very real crossroads. If chemo has done the first hard job, fulvestrant maintenance may keep HR-positive, HER2-negative metastatic breast cancer controlled longer than capecitabine, with fewer severe side effects.
That is the kind of plot twist patients can actually use.
References
Wu W, Yang Y, Chen H, et al. Fulvestrant versus capecitabine as maintenance therapy in hormone receptor-positive, HER2-negative metastatic breast cancer after first-line chemotherapy (FAMILY): a multicenter, open-label, randomized, phase 3 trial. Signal Transduction and Targeted Therapy. 2026. doi:10.1038/s41392-026-02720-6
O’Sullivan CC, Clarke R, Goetz MP, Robertson J. Cyclin-dependent kinase 4/6 inhibitors for treatment of hormone receptor-positive, ERBB2-negative breast cancer: a review. JAMA Oncology. 2023;9(9):1273-1282. doi:10.1001/jamaoncol.2023.2000
Gennari A, André F, Barrios CH, et al. Current and emerging treatment approaches for hormone receptor-positive/HER2-negative metastatic breast cancer. Cancer Treatment Reviews. 2024;123:102670. doi:10.1016/j.ctrv.2023.102670
Ferro A, Campora M, Caldara A, et al. Novel treatment strategies for hormone receptor-positive, HER2-negative metastatic breast cancer. Journal of Clinical Medicine. 2024;13(12):3611. doi:10.3390/jcm13123611
Bidard FC, Kaklamani VG, Neven P, et al. Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer. Nature Reviews Clinical Oncology. 2024. doi:10.1038/s41571-024-00935-6
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.